Best ASX stocks under $10 to buy now

Many investors often overlook ASX stocks which trade under $10 despite several of them being very high-quality businesses with excellent market positions.

The following are the best ASX stocks under $10 which have delivered solid performances over the years and have tremendous long-term growth potential.

 ASX stocks under $10 to buy now

Catapult Sports Limited (ASX: CAT) 

Sigma Healthcare Limited (ASX: SIG) 

Spark New Zealand Limited (ASX: SPK) 

Catapult Sports Limited (ASX: CAT) 

is one of the best ASX stocks under $10 and currently has a market capitalisation of $1 billion. It has a great position as a global sports technology company that provides athlete monitoring, video analytics, scouting and performance optimisation solutions to more than 3,800 professional teams worldwide.

The company has also built a large proprietary dataset over more than 15 years which contains billions of data points related to athlete performance and video analysis.
This data advantage has improved the company’s competitive position because it is difficult for competitors to replicate while higher solution penetration and broader use cases support the scalability and strength of the core business model.

The company reported revenue of US$67.6 million for the September 2025 half year while EBITDA stood at around US$9 million.
Management further highlighted a long-term ambition to eventually scale toward US$1 billion in ACV through its “land and expand” growth strategy.

Sigma Healthcare Limited (ASX: SIG) 

is one of the best ASX stocks under $10 and currently has a market capitalisation of approximately $33.2 billion.
The company has built a strong position in the healthcare and pharmacy retail sector through the rapid expansion of the Chemist Warehouse network across Australia and international markets.
Sigma in 1H26 reported revenue growth of 14.9% to $5.5 billion while Normalised EBIT increased 18.7% to $582.9 million and Normalised NPAT rose 19.2% to $392 million compared with the prior corresponding period.

Australian Chemist Warehouse branded store sales increased 17.2% while international store sales rose 24.5%.
Management expects strong trading momentum to continue in 2H26 with additional Chemist Warehouse store openings planned across several countries along with ongoing progress towards the $100 million annual synergy target by FY29.

The company also benefits from a highly scalable business model together with strong brand recognition, defensive healthcare demand and rising operating leverage which positions the business for sustained long-term earnings growth.

Spark New Zealand Limited (ASX: SPK) 

is a solid ASX stock under $10 and currently has a market capitalisation of approximately $3.24 billion with an annual dividend yield of 9.91%.

The company in H1 FY26 reported adjusted EBITDAI of NZ$471 million which rose 5.1% while adjusted NPAT increased 30.4% to NZ$73 million backed by high switching costs for consumers.
Free cash flow jumped 84% to NZ$107 million even though adjusted revenue declined 1.1% to NZ$1.917 billion compared with the prior corresponding period.

Recent developments improved the company’s outlook after Spark completed the sale of a 75% stake in its data centre business for NZ$453 million which improved balance sheet.
The company also invested heavily in network quality, AI integration and customer experience which included satellite-to-mobile services along with AI-powered automation initiatives.

Management reaffirmed FY26 guidance with adjusted EBITDAI expected between NZ$1.01 billion and NZ$1.07 billion while maintaining a dividend payout ratio of 100% of free cash flow.

(Source: Company Reports)